VVUS hits a bottom. Breaking out of falling wedge formation

- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS

PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)

Disclosure: Long $2 Jan 2017 calls @1.10/contract